BENGAMIDE DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF CANCER
Preparation of bengamide compounds (3-alkenoylamino-hexahydroazepin-2-one derivatives) (A) involves fermenting Myxococcus virescens ST200611 (DSM 15898) (or its variants and/or mutants). Some of the bengamide derivatives (A) (i.e. 3-(2-methoxy-8-methyl-3,4,5-trihydroxydec-6E-enoylamino-hexahydroazep...
Gespeichert in:
| Hauptverfasser: | , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng ; fre ; ger |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | HAAG-RICHTER, SABINE HOFFMANN, HOLGER KURZ, MICHAEL TIETGEN, HEIKO |
| description | Preparation of bengamide compounds (3-alkenoylamino-hexahydroazepin-2-one derivatives) (A) involves fermenting Myxococcus virescens ST200611 (DSM 15898) (or its variants and/or mutants). Some of the bengamide derivatives (A) (i.e. 3-(2-methoxy-8-methyl-3,4,5-trihydroxydec-6E-enoylamino-hexahydroazepin-2-ones) are new. Preparation of bengamide compounds of formula (A) or their salts involves fermenting Myxococcus virescens ST200611 (DSM 15898) (or its variants and/or mutants) in a culture medium, isolating the obtained (A) from the culture medium and optionally derivatizing and/or salifying the product. [Image] R 1H or 1-6C alkyl; R 2H or OH; R 3H or 2-7C alkanoyl; R 4Me or Et. Independent claims are included for: (1) bengamide derivatives of formula (B) (this is structure (A) where R 4 = Et) and their salts as new compounds; (2) the new microorganism Myxococcus virescens ST200611 (DSM 15898); and (3) the use of Myxococcus virescens ST200611 (DSM 15898) (or its variants and/or mutants) for the production of (A). ACTIVITY : Cytostatic. A specific diastereomer of 3-(2-methoxy-8-methyl-3,4,5-trihydroxydec-6E-enoylamino)-hexahydroazepin-2-one (A1) had TC 5 0 values of 6 mu M and 10 mu M for inhibition of proliferation of Hep-G2 and Colo 205 cells respectively. MECHANISM OF ACTION : Mitosis inhibitor; Cell cycle regulator. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_EP1680405B1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>EP1680405B1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_EP1680405B13</originalsourceid><addsrcrecordid>eNrjZHB0cvVzd_T1dHFVcHEN8gxzDPEMcw1WcPRzUQgNdlUI8XANcvV3U3DzDwKxFUKCXB1DfF39QhSAgs6Ofs6uQTwMrGmJOcWpvFCam0HBzTXE2UM3tSA_PrW4IDE5NS-1JN41wNDMwsDEwNTJ0JgIJQBeDCou</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>BENGAMIDE DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF CANCER</title><source>esp@cenet</source><creator>HAAG-RICHTER, SABINE ; HOFFMANN, HOLGER ; KURZ, MICHAEL ; TIETGEN, HEIKO</creator><creatorcontrib>HAAG-RICHTER, SABINE ; HOFFMANN, HOLGER ; KURZ, MICHAEL ; TIETGEN, HEIKO</creatorcontrib><description>Preparation of bengamide compounds (3-alkenoylamino-hexahydroazepin-2-one derivatives) (A) involves fermenting Myxococcus virescens ST200611 (DSM 15898) (or its variants and/or mutants). Some of the bengamide derivatives (A) (i.e. 3-(2-methoxy-8-methyl-3,4,5-trihydroxydec-6E-enoylamino-hexahydroazepin-2-ones) are new. Preparation of bengamide compounds of formula (A) or their salts involves fermenting Myxococcus virescens ST200611 (DSM 15898) (or its variants and/or mutants) in a culture medium, isolating the obtained (A) from the culture medium and optionally derivatizing and/or salifying the product. [Image] R 1H or 1-6C alkyl; R 2H or OH; R 3H or 2-7C alkanoyl; R 4Me or Et. Independent claims are included for: (1) bengamide derivatives of formula (B) (this is structure (A) where R 4 = Et) and their salts as new compounds; (2) the new microorganism Myxococcus virescens ST200611 (DSM 15898); and (3) the use of Myxococcus virescens ST200611 (DSM 15898) (or its variants and/or mutants) for the production of (A). ACTIVITY : Cytostatic. A specific diastereomer of 3-(2-methoxy-8-methyl-3,4,5-trihydroxydec-6E-enoylamino)-hexahydroazepin-2-one (A1) had TC 5 0 values of 6 mu M and 10 mu M for inhibition of proliferation of Hep-G2 and Colo 205 cells respectively. MECHANISM OF ACTION : Mitosis inhibitor; Cell cycle regulator.</description><language>eng ; fre ; ger</language><subject>BEER ; BIOCHEMISTRY ; CHEMISTRY ; ENZYMOLOGY ; FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE ; HETEROCYCLIC COMPOUNDS ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; MICROBIOLOGY ; MUTATION OR GENETIC ENGINEERING ; ORGANIC CHEMISTRY ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS ; SPIRITS ; VINEGAR ; WINE</subject><creationdate>2009</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20090107&DB=EPODOC&CC=EP&NR=1680405B1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20090107&DB=EPODOC&CC=EP&NR=1680405B1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>HAAG-RICHTER, SABINE</creatorcontrib><creatorcontrib>HOFFMANN, HOLGER</creatorcontrib><creatorcontrib>KURZ, MICHAEL</creatorcontrib><creatorcontrib>TIETGEN, HEIKO</creatorcontrib><title>BENGAMIDE DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF CANCER</title><description>Preparation of bengamide compounds (3-alkenoylamino-hexahydroazepin-2-one derivatives) (A) involves fermenting Myxococcus virescens ST200611 (DSM 15898) (or its variants and/or mutants). Some of the bengamide derivatives (A) (i.e. 3-(2-methoxy-8-methyl-3,4,5-trihydroxydec-6E-enoylamino-hexahydroazepin-2-ones) are new. Preparation of bengamide compounds of formula (A) or their salts involves fermenting Myxococcus virescens ST200611 (DSM 15898) (or its variants and/or mutants) in a culture medium, isolating the obtained (A) from the culture medium and optionally derivatizing and/or salifying the product. [Image] R 1H or 1-6C alkyl; R 2H or OH; R 3H or 2-7C alkanoyl; R 4Me or Et. Independent claims are included for: (1) bengamide derivatives of formula (B) (this is structure (A) where R 4 = Et) and their salts as new compounds; (2) the new microorganism Myxococcus virescens ST200611 (DSM 15898); and (3) the use of Myxococcus virescens ST200611 (DSM 15898) (or its variants and/or mutants) for the production of (A). ACTIVITY : Cytostatic. A specific diastereomer of 3-(2-methoxy-8-methyl-3,4,5-trihydroxydec-6E-enoylamino)-hexahydroazepin-2-one (A1) had TC 5 0 values of 6 mu M and 10 mu M for inhibition of proliferation of Hep-G2 and Colo 205 cells respectively. MECHANISM OF ACTION : Mitosis inhibitor; Cell cycle regulator.</description><subject>BEER</subject><subject>BIOCHEMISTRY</subject><subject>CHEMISTRY</subject><subject>ENZYMOLOGY</subject><subject>FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE</subject><subject>HETEROCYCLIC COMPOUNDS</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>MICROBIOLOGY</subject><subject>MUTATION OR GENETIC ENGINEERING</subject><subject>ORGANIC CHEMISTRY</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><subject>SPIRITS</subject><subject>VINEGAR</subject><subject>WINE</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2009</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZHB0cvVzd_T1dHFVcHEN8gxzDPEMcw1WcPRzUQgNdlUI8XANcvV3U3DzDwKxFUKCXB1DfF39QhSAgs6Ofs6uQTwMrGmJOcWpvFCam0HBzTXE2UM3tSA_PrW4IDE5NS-1JN41wNDMwsDEwNTJ0JgIJQBeDCou</recordid><startdate>20090107</startdate><enddate>20090107</enddate><creator>HAAG-RICHTER, SABINE</creator><creator>HOFFMANN, HOLGER</creator><creator>KURZ, MICHAEL</creator><creator>TIETGEN, HEIKO</creator><scope>EVB</scope></search><sort><creationdate>20090107</creationdate><title>BENGAMIDE DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF CANCER</title><author>HAAG-RICHTER, SABINE ; HOFFMANN, HOLGER ; KURZ, MICHAEL ; TIETGEN, HEIKO</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_EP1680405B13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre ; ger</language><creationdate>2009</creationdate><topic>BEER</topic><topic>BIOCHEMISTRY</topic><topic>CHEMISTRY</topic><topic>ENZYMOLOGY</topic><topic>FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE</topic><topic>HETEROCYCLIC COMPOUNDS</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>MICROBIOLOGY</topic><topic>MUTATION OR GENETIC ENGINEERING</topic><topic>ORGANIC CHEMISTRY</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><topic>SPIRITS</topic><topic>VINEGAR</topic><topic>WINE</topic><toplevel>online_resources</toplevel><creatorcontrib>HAAG-RICHTER, SABINE</creatorcontrib><creatorcontrib>HOFFMANN, HOLGER</creatorcontrib><creatorcontrib>KURZ, MICHAEL</creatorcontrib><creatorcontrib>TIETGEN, HEIKO</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>HAAG-RICHTER, SABINE</au><au>HOFFMANN, HOLGER</au><au>KURZ, MICHAEL</au><au>TIETGEN, HEIKO</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>BENGAMIDE DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF CANCER</title><date>2009-01-07</date><risdate>2009</risdate><abstract>Preparation of bengamide compounds (3-alkenoylamino-hexahydroazepin-2-one derivatives) (A) involves fermenting Myxococcus virescens ST200611 (DSM 15898) (or its variants and/or mutants). Some of the bengamide derivatives (A) (i.e. 3-(2-methoxy-8-methyl-3,4,5-trihydroxydec-6E-enoylamino-hexahydroazepin-2-ones) are new. Preparation of bengamide compounds of formula (A) or their salts involves fermenting Myxococcus virescens ST200611 (DSM 15898) (or its variants and/or mutants) in a culture medium, isolating the obtained (A) from the culture medium and optionally derivatizing and/or salifying the product. [Image] R 1H or 1-6C alkyl; R 2H or OH; R 3H or 2-7C alkanoyl; R 4Me or Et. Independent claims are included for: (1) bengamide derivatives of formula (B) (this is structure (A) where R 4 = Et) and their salts as new compounds; (2) the new microorganism Myxococcus virescens ST200611 (DSM 15898); and (3) the use of Myxococcus virescens ST200611 (DSM 15898) (or its variants and/or mutants) for the production of (A). ACTIVITY : Cytostatic. A specific diastereomer of 3-(2-methoxy-8-methyl-3,4,5-trihydroxydec-6E-enoylamino)-hexahydroazepin-2-one (A1) had TC 5 0 values of 6 mu M and 10 mu M for inhibition of proliferation of Hep-G2 and Colo 205 cells respectively. MECHANISM OF ACTION : Mitosis inhibitor; Cell cycle regulator.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng ; fre ; ger |
| recordid | cdi_epo_espacenet_EP1680405B1 |
| source | esp@cenet |
| subjects | BEER BIOCHEMISTRY CHEMISTRY ENZYMOLOGY FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MUTATION OR GENETIC ENGINEERING ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS VINEGAR WINE |
| title | BENGAMIDE DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF CANCER |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T21%3A29%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=HAAG-RICHTER,%20SABINE&rft.date=2009-01-07&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EEP1680405B1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |